新冠在肾脏替代治疗成人中的发病率、特征与结局:区域登记研究
本研究为前瞻性多中心区域登记研究,比较2020年3月2日至5月25日比利时弗兰德斯地区接受肾脏替代治疗的成人患者与普通人群的SARS-CoV-2感染情况。血液透析患者年龄标化累积发病率5.3%,肾移植患者1.4%,普通人群0.6%;血液透析患者年龄标化病死率19.9%,肾移植患者23.0%,普通人群15.3%。研究认为肾脏替代治疗患者感染相关病死率高,但疫情对该人群总体影响有限。
要点
- 血液透析患者年龄标化新冠累积发病率5.3%,高于普通人群0.6%。
- 血液透析患者年龄标化新冠病死率19.9%,肾移植患者23.0%。
- 仅0.18%肾移植患者死于SARS-CoV-2感染。
核心结论
- 肾脏替代治疗患者SARS-CoV-2感染相关病死率高。
- 疫情对弗兰德斯地区肾脏替代治疗人群的总体影响有限。
- 计算超额死亡和年龄标化能更可靠反映新冠死亡负担。
研究设计与样本
- 前瞻性、多中心、区域登记研究。
- 纳入2020年3月2日至5月25日比利时弗兰德斯地区所有接受肾脏替代治疗的成人患者。
- 比较肾脏替代治疗患者与普通人群的SARS-CoV-2感染情况。
主要发现
- 血液透析患者4297例,粗累积发病率5.3%,年龄标化累积发病率2.5%。
- 肾移植患者3293例,粗累积发病率1.4%,年龄标化累积发病率1.6%。
- 普通人群累积发病率0.6%。
- 血液透析患者粗累积病死率29.6%,年龄标化累积病死率19.9%。
- 肾移植患者粗累积病死率14.0%,年龄标化累积病死率23.0%;普通人群累积病死率15.3%。
临床怎么用
- 应关注肾脏替代治疗患者SARS-CoV-2感染的高病死率。
- 评估新冠死亡负担时建议采用年龄标化和超额死亡计算。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection disproportionally affects frail, elderly patients and those with multiple chronic comorbidities. Whether patients on RRT have an additional risk because of their specific exposure and complex immune dysregulation is controversial. METHODS: To describe the incidence, characteristics, and outcomes of SARS-CoV-2 infection, we conducted a prospective, multicenter, region-wide registry study in adult patients on RRT versus the general population from March 2 to May 25, 2020. This study comprised all patients undergoing RRT in the Flanders region of Belgium, a country that has been severely affected by coronavirus disease 2019 (COVID-19). RESULTS: At the end of the epidemic wave, crude and age-standardized cumulative incidence rates of SARS-CoV-2 infection were 5.3% versus 2.5%, respectively, among 4297 patients on hemodialysis, and 1.4% versus 1.6%, respectively, among 3293 patients with kidney transplants (compared with 0.6% in the general population). Crude and age-standardized cumulative mortality rates were 29.6% versus 19.9%, respectively, among patients on hemodialysis, and 14.0% versus 23.0%, respectively, among patients with transplants (compared with 15.3% in the general population). We found no excess mortality in the hemodialysis population when compared with mean mortality rates during the same 12-week period in 2015-2019 because COVID-19 mortality was balanced by lower than expected mortality among uninfected patients. Only 0.18% of the kidney transplant population died of SARS-CoV-2 infection. CONCLUSIONS: Mortality associated with SARS-CoV-2 infection is high in patients on RRT. Nevertheless, the epidemic's overall effect on the RRT population remained remarkably limited in Flanders. Calculation of excess mortality and age standardization provide a more reliable picture of the mortality burden of COVID-19 among patients on RRT.
引用
- De Meester J, De Bacquer D, Naesens M, et al. Incidence, Characteristics, and Outcome of COVID-19 in Adults on Kidney Replacement Therapy: A Regionwide Registry Study. J Am Soc Nephrol. 2020. PMID: 33154174. doi:10.1681/ASN.2020060875
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。